All Specialties CardiologyNephrologyEndocrinologyPrimary CarePrescribing Information Previous Next What is the impact of SGLT2 inhibitor trials in HFpEF? FeaturingProfessor Andrew Coats | Australia Home List of Products HCPs All Specialties Shorts What is the impact of SGLT2 inhibitor trials in HFpEF? Related content Document ID: PC-SG-101865 Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2) Watch now Opens in new tab Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Full; Day 2) Watch now Opens in new tab Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab Read more Subodh Verma (Canada) Why should empagliflozin be your first choice in heart failure management? Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2) Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Full; Day 2) Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab
Read more Subodh Verma (Canada) Why should empagliflozin be your first choice in heart failure management? Watch now Opens in new tab